These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34447608)

  • 1. Digital Image Analysis for Estimating Stromal CD8+ Tumor-Infiltrating Lymphocytes in Lung Adenocarcinoma.
    Jhun I; Shepherd D; Hung YP; Madrigal E; Le LP; Mino-Kenudson M
    J Pathol Inform; 2021; 12():28. PubMed ID: 34447608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hotspot enumeration of CD8+ tumor-infiltrating lymphocytes using digital image analysis in triple-negative breast cancer yields consistent results.
    McIntire PJ; Zhong E; Patel A; Khani F; D'Alfonso TM; Chen Z; Shin SJ; Ginter PS
    Hum Pathol; 2019 Mar; 85():27-32. PubMed ID: 30381263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digital image analysis in pathologist-selected regions of interest predicts survival more accurately than whole-slide analysis: a direct comparison study in 153 gastric carcinomas.
    Heo YJ; Lee T; Byeon SJ; Kim EJ; Shin HC; Kim B; Kang SY; Ha SY; Kim KM
    J Pathol Clin Res; 2021 Jan; 7(1):42-51. PubMed ID: 32885920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative digital image analysis of tumor-infiltrating lymphocytes in HER2-positive breast cancer.
    Abe N; Matsumoto H; Takamatsu R; Tamaki K; Takigami N; Uehara K; Kamada Y; Tamaki N; Motonari T; Unesoko M; Nakada N; Zaha H; Yoshimi N
    Virchows Arch; 2020 May; 476(5):701-709. PubMed ID: 31873876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer.
    Donnem T; Hald SM; Paulsen EE; Richardsen E; Al-Saad S; Kilvaer TK; Brustugun OT; Helland A; Lund-Iversen M; Poehl M; Olsen KE; Ditzel HJ; Hansen O; Al-Shibli K; Kiselev Y; Sandanger TM; Andersen S; Pezzella F; Bremnes RM; Busund LT
    Clin Cancer Res; 2015 Jun; 21(11):2635-43. PubMed ID: 25680376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.
    Yoneda K; Kuwata T; Kanayama M; Mori M; Kawanami T; Yatera K; Ohguri T; Hisaoka M; Nakayama T; Tanaka F
    Br J Cancer; 2019 Sep; 121(6):490-496. PubMed ID: 31388183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digitally quantified CD8+ cells: the best candidate marker for an immune cell score in non-small cell lung cancer?
    Kilvaer TK; Paulsen EE; Andersen S; Rakaee M; Bremnes RM; Busund LR; Donnem T
    Carcinogenesis; 2020 Dec; 41(12):1671-1681. PubMed ID: 33035322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
    Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
    Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
    Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
    J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death ligand 1 expression and CD8
    Zhou J; Gong Z; Jia Q; Wu Y; Yang ZZ; Zhu B
    Biochem Biophys Res Commun; 2018 Apr; 498(4):751-757. PubMed ID: 29526752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History.
    Mignon S; Willard-Gallo K; Van den Eynden G; Salgado R; Decoster L; Marien KM; Vansteenkiste JF; Teugels E; De Grève J
    Pathol Oncol Res; 2020 Apr; 26(2):1221-1228. PubMed ID: 31228073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
    Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy.
    Wei Z; Zhan X; Fan L; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Meng M; Ni Y; Li Q
    Int J Hyperthermia; 2018; 35(1):591-598. PubMed ID: 30307348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
    Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
    Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression.
    Lin Z; Gu J; Cui X; Huang L; Li S; Feng J; Liu B; Zhou Y
    J Cancer; 2019; 10(1):211-222. PubMed ID: 30662542
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer.
    Rakaee M; Kilvaer TK; Dalen SM; Richardsen E; Paulsen EE; Hald SM; Al-Saad S; Andersen S; Donnem T; Bremnes RM; Busund LT
    Hum Pathol; 2018 Sep; 79():188-198. PubMed ID: 29885403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases.
    Batur S; Dulger O; Durak S; Yumuk PF; Caglar HB; Bozkurtlar E; Bozkurt S; Tastekin E; Cicin I; Ahiskali R; Rzazade R; Cakir A; Oz B
    Bosn J Basic Med Sci; 2020 Aug; 20(3):329-335. PubMed ID: 31999935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer.
    Ahn S; Chung YR; Seo AN; Kim M; Woo JW; Park SY
    PLoS One; 2020; 15(5):e0233037. PubMed ID: 32401825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.